Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 7/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALDH1A3 | P47895 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 3/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1472422 | 0.85 | NR4A2 (0.83) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3432415 | 0.84 | NR4A2 (0.78) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472288 | 0.83 | NR4A2 (0.80) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472658 | 0.83 | NR4A2 (0.80) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3428756 | 0.83 | NR4A2 (0.65) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472851 | 0.82 | NR4A2 (1.00) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1475047 | 0.82 | NR4A2 (0.78) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL3429924 | 0.81 | NR4A2 (0.66) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472927 | 0.81 | NR4A2 (0.72) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 | |
| SCHEMBL1472627 | 0.81 | NR4A2 (0.84) | NR4A2KCNH2CYP2C9ALDH1A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262805-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | claimed |
| CN-102036987-B | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo [1,2-a ] pyridines, process for their preparation and their therapeutic use | SANOFI AVENTIS | 2014-01-01 | — | — | CN | claimed |
| US-8338451-B2 | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2012-12-25 | — | — | US | claimed |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | claimed |
| EP-2262805-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | claimed |
| WO-2009144395-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | claimed |
| CN-103254221-B | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo [1,2-a ] pyridine and process for their preparation | SANOFI AVENTIS | 2014-11-19 | — | — | CN | disclosed |
| EP-2262805-B1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| CN-102036987-B | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo [1,2-a ] pyridines, process for their preparation and their therapeutic use | SANOFI AVENTIS | 2014-01-01 | — | — | CN | disclosed |
| CN-103254221-A | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo [1,2-a ] pyridines, process for their preparation and their therapeutic use | SANOFI AVENTIS | 2013-08-21 | — | — | CN | disclosed |
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (US) | 2013-05-16 | — | — | US | disclosed |
| US-8338451-B2 | Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
| EP-2262805-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009144395-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123288-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR4A2 1640/4885KCNH2 1938/4885CYP2C9 451/4885 |
| US-20110065727-A1 | POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF | ABL1, JAK2, REN | NR4A2 1640/4885KCNH2 1938/4885CYP2C9 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.